Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 22Phase 1/2 13Phase 3 5Phase 4 2Phase NA 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 8Lymphoma 6Myelodysplastic Syndromes 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, T-Cell 2Leukemia, Monocytic, Acute 2Anemia, Refractory, with Excess of Blasts 2Recurrence 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Congenital Abnormalities 1Burkitt Lymphoma 1Anemia, Refractory 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × Cytarabine × Clear all
NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡